Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brittany Buckmaster

Physician Assistant, Surgical Dallas, TX Physician Assistant

NPI 1053714618 CMS profile 10782004

3410 Worth St, Ste 235, Dallas, TX 75246

Open in the dashboard

General payments

$6,552

58 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brittany Buckmaster of Dallas, TX is reported in the CMS Open Payments database as having received $6,552 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $490 7
2024 General $595 8
2023 General $815 10
2022 General $3,237 19
2021 General $1,414 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brittany Buckmaster
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Brittany Buckmaster were reported at $490. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Brittany Buckmaster Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,414 $111 $36–$285 $132
2022 $3,237 $126 $44–$350 $149
2023 $815 $137 $47–$355 $160
2024 $595 $146 $49–$384 $164
2025 $490 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medical Device Business Services, Inc. $3,410 7 payments
  2. Enterra Medical, Inc. $1,228 8 payments
  3. Intuitive Surgical, Inc. $405 6 payments
  4. Ethicon US, LLC $391 6 payments
  5. Davol Inc. $216 5 payments
  6. TELA Bio, Inc. $171 1 payment
  7. Allergan Inc. $139 8 payments
  8. Integra LifeSciences Corporation $130 4 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $104 1 payment
  10. Abiomed $95 1 payment
  11. Other $263 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $3,300 4 payments
  2. Food and Beverage $3,026 52 payments
  3. Travel and Lodging $226 2 payments
Products named General payments · program years 2021–2025
  1. Da Vinci Surgical System $405 6 payments
  2. LINX Reflux Management System $295 2 payments
  3. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $192 10 payments
  4. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $171 1 payment
  5. Phasix Mesh $129 2 payments
  6. RELISTOR $104 1 payment
  7. Impella $95 1 payment
  8. Integra Recon-Skin And Wound $75 3 payments
  9. Integra Recon-Skin And Wound $75 3 payments
  10. INTEGRA DERMAL REGENERATION TEMPLATE $75 3 payments
  11. Other $682 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

302

Median for Physician Assistant: 241

Drug cost

$39,549

Median for Physician Assistant: $4,110

Branded share of claims

13.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gimoti Metoclopramide Hcl Brand 14 $28,176
Sucralfate Generic 34 $4,638
Dexlansoprazole Dr Dexlansoprazole Brand 11 $3,391
Esomeprazole Magnesium Generic 15 $1,457
Omeprazole Generic 95 $870
Pantoprazole Sodium Generic 63 $433
Metoclopramide Hcl Generic 37 $367
Ondansetron Odt Ondansetron Brand 17 $154
Amitriptyline Hcl Generic 16 $63

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$12,888

Medicare's payments for the services billed

Medicare patients

94

Average age 73

Services billed

140

62 women, 32 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 37%
Depression 37%
Diabetes 30%
Osteoporosis 24%
COPD 22%
Chronic kidney disease 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record